Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adaptive Biotechnologies Corporation    ADPT

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020

10/13/2020 | 04:05pm EST

SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter ended September 30, 2020 after market close on Tuesday, November 10, 2020. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have two commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE MEDIA
Beth Keshishian
917-912-7195
media@adaptivebiotech.com

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

Primary Logo


© GlobeNewswire 2020
All news about ADAPTIVE BIOTECHNOLOGIES CORPORATION
11/24ADAPTIVE BIOTECHNOLOGIES : and Collaborators to Present Data from More Than 35 A..
AQ
11/23ADAPTIVE BIOTECHNOLOGIES : and Collaborators to Present Data from More Than 35 A..
AQ
11/23Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 ..
GL
11/16ADAPTIVE BIOTECHNOLOGIES : Preliminary Data from Real-World Study Demonstrate T-..
AQ
11/13ADAPTIVE BIOTECHNOLOGIES : Preliminary Data from Real-World Study Demonstrate T-..
AQ
11/13Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms..
GL
11/12ADAPTIVE BIOTECHNOLOGIES CORP : Other Events (form 8-K)
AQ
11/10ADAPTIVE BIOTECHNOLOGIES : Management's Discussion and Analysis of Financial Con..
AQ
11/10ADAPTIVE BIOTECHNOLOGIES CORP : Results of Operations and Financial Condition, F..
AQ
11/10ADAPTIVE BIOTECHNOLOGIES : 3Q Earnings Snapshot
AQ
More news
Financials (USD)
Sales 2020 94,8 M - -
Net income 2020 -142 M - -
Net cash 2020 509 M - -
P/E ratio 2020 -43,4x
Yield 2020 -
Capitalization 6 428 M 6 428 M -
EV / Sales 2020 62,4x
EV / Sales 2021 37,0x
Nbr of Employees 453
Free-Float 94,2%
Chart ADAPTIVE BIOTECHNOLOGIES CORPORATION
Duration : Period :
Adaptive Biotechnologies Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAPTIVE BIOTECHNOLOGIES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 58,17 $
Last Close Price 47,00 $
Spread / Highest target 40,4%
Spread / Average Target 23,8%
Spread / Lowest Target -2,13%
EPS Revisions
Managers
NameTitle
Chad Robins Chairman & Chief Executive Officer
Julie Rubinstein President
Nancy L. Hill Senior Vice President-Operations
Chad M. Cohen CFO, Principal Financial & Accounting Officer
Harlan Robins Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ADAPTIVE BIOTECHNOLOGIES CORPORATION57.09%6 428
WUXI APPTEC CO., LTD.56.53%37 916
IQVIA HOLDINGS INC.9.26%32 365
BEIGENE, LTD.72.47%26 060
HANGZHOU TIGERMED CONSULTING CO.,LTD79.46%15 070
NEUROCRINE BIOSCIENCES, INC.-11.51%8 928